Bristol Myers Squibb Company
NEWS
BMS announced that the FDA approved Sotyktu for adults with moderate-to-severe plaque psoriasis, marking this indication’s first oral treatment innovation in nearly a decade.
The ESMO conference is serving as a post-mortem on the trials that sunk the multi-billion-dollar partnership between Bristol-Myers Squibb and Nektar Therapeutics.
Gilead, Merck, Daiichi Sankyo, HUTCHMED and BMS previewed data to be presented at the European Society for Medical Oncology Congress 2022, taking place Sept. 9-13.
Factor XIa inhibitors developed by Bayer and the duo of BMS and Janssen Pharmaceuticals missed Phase II endpoints in data presented at ESC.
Drug development can be done better, faster and less expensively. The industry is facing up to that reality, moving a variety of disruptive innovations forward with the blessing of regulators.
BMS, 2seventy bio, HUTCHMED and AstraZeneca celebrate cancer trial wins, while mutated zebrafish eyes reveal potentially important insights into cell death.
In partnership with GentiBio, BMS aims to harness the capabilities of engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with IBD.
Bristol Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) as an adjuvant treatment for localized renal cell carcinoma (RCC) failed to hit the primary endpoint.
As the second financial quarter of the year comes to a close, pharma and biotech companies are releasing their financial results. For more information on the top-earning companies, read on.
JOBS
IN THE PRESS